Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 13/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19186042 | 1.00 | RNASEL (0.69) | RNASEL | |
| SCHEMBL20075463 | 0.95 | RNASEL (0.63) | RNASEL | |
| SCHEMBL19696038 | 0.95 | RNASEL (0.61) | RNASEL | |
| SCHEMBL19250012 | 0.94 | RNASEL (0.60) | RNASEL | |
| SCHEMBL22326788 | 0.94 | RNASEL (0.62) | RNASEL | |
| SCHEMBL22326712 | 0.94 | RNASEL (0.62) | RNASEL | |
| SCHEMBL21362202 | 0.93 | RNASEL (0.60) | RNASEL | |
| SCHEMBL20324586 | 0.92 | RNASEL (0.60) | RNASEL | |
| SCHEMBL23430014 | 0.92 | RNASEL (0.82) | RNASEL | |
| SCHEMBL21140197 | 0.92 | RNASEL (0.82) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-10450341-B2 | Cyclic di-nucleotides as modulators of STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | RNASEL 3962/4885 |
| US-10450341-B2 | Cyclic di-nucleotides as modulators of STING | STING1, CGAS, IRF3 | RNASEL 3351/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | RNASEL 3962/4885 |
| US-20170158724-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | RNASEL 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.